Mentioned On
Episode Mentions
Pharma and BioTech Daily · May 7, 2026
Bayer's $2.4B Perfuse Deal Shakes Up Eye Care | Pharma and Biotech Daily
“Reported promising Phase 2 results in skin disease treatment despite challenges from placebo comparisons”
Ophthalmology Portfolio ExpansionAI-Driven Drug Development CommercializationGLP-1 Agonist Obesity Treatment Competition
View Analysis